Biotech companies at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
61 biotech companies are at ASH 2026 — 3 presentations on the program and 58 with a booth in the exhibit hall. Most represented: Moderna (1 on the program), Agios Pharmaceuticals (1 on the program). 60 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–11 of 61 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Moderna Cambridge, MA | |
Biotechnology company developing mRNA medicines and vaccines. | Session Back to Business Breakfast Networking breakfast for hematology innovators and investors, introducing a new society platform for turning blood research into companies and products. Talk Session Fireside Chats on Innovation in a Changing Regulatory Landscape How FDA priorities, investor reactions to regulatory uncertainty, and new modeling tools shape the development of hematology discoveries into therapies. Talk |
Agios Pharmaceuticals Cambridge, MA | |
Commercial-stage biopharmaceutical company with roots in hematology, developing medicines for rare diseases. | Booth Exhibiting at Booth 929 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, whose medicines include the BTK inhibitor zanubrutinib for CLL and other B-cell cancers. | Booth Exhibiting at Booth 421 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. |
Genmab Copenhagen, Denmark | |
Danish antibody company developing bispecific antibodies and antibody-drug conjugates, including epcoritamab for lymphoma. | Booth Exhibiting at Booth 3229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 3:00pm–6:00pm Optimizing Integration of BsAb-Based Therapies for FL and DLBCL: Expert Perspectives on New Standards and Future Directions How bispecific antibodies for follicular and diffuse large B-cell lymphoma differ in structure, dosing, and safety, and how to sequence them in community care. |
Geron Foster City, CA | |
Biopharmaceutical company marketing imetelstat (RYTELO), a telomerase inhibitor for lower-risk MDS, and studying it in myelofibrosis. | Booth Exhibiting at Booth 1929 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. |
ADC Therapeutics Lausanne, Switzerland | |
Antibody-drug conjugate developer that markets loncastuximab tesirine (Zynlonta) for relapsed or refractory diffuse large B-cell lymphoma. | Booth Exhibiting at Booth 2529 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Redefining DLBCL — How Biomarker- and Mechanism-Driven Strategies Are Reshaping Management Across the Disease Continuum Using molecular subtypes of diffuse large B-cell lymphoma to choose frontline treatment among polatuzumab regimens, bispecific antibodies, and CAR-T. |
Incyte Wilmington, DE | |
Biopharmaceutical company discovering, developing and marketing its own medicines in oncology and in inflammation and autoimmunity. | Booth Exhibiting at Booth 228, 1113 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. |
Kura Oncology San Diego, CA | |
Precision oncology company developing ziftomenib, a menin inhibitor for acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements, and other targeted cancer drugs. | Booth Exhibiting at Booth 2229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. |
PharmaEssentia Taipei, Taiwan | |
Taiwan-based biopharmaceutical company making biologics for hematology and oncology, including an approved interferon therapy for polycythemia vera. | Booth Exhibiting at Booth 3739 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 11:00am–2:00pm Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails. |
Rigel Pharmaceuticals South San Francisco, CA | |
Biotech developing and selling therapies for blood disorders and cancer, with three FDA-approved products including fostamatinib and olutasidenib. | Booth Exhibiting at Booth 613 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Current Management Paradigms in Acute Myeloid Leukemia – A Second Opinion Case Review Difficult acute myeloid leukemia cases where doctors sought second opinions, paired with reviews of recent data, current management, and ongoing trials. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. |
Blueprint Medicines Cambridge, MA | |
Precision therapy company, now part of Sanofi, known for avapritinib for systemic mastocytosis. | Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. |
Instantly find 20 buyers from biotech companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction